JP2012017341A5 - - Google Patents

Download PDF

Info

Publication number
JP2012017341A5
JP2012017341A5 JP2011224347A JP2011224347A JP2012017341A5 JP 2012017341 A5 JP2012017341 A5 JP 2012017341A5 JP 2011224347 A JP2011224347 A JP 2011224347A JP 2011224347 A JP2011224347 A JP 2011224347A JP 2012017341 A5 JP2012017341 A5 JP 2012017341A5
Authority
JP
Japan
Prior art keywords
egfr
use according
heterodimer
tumor
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011224347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012017341A (ja
JP5719270B2 (ja
Filing date
Publication date
Priority claimed from US09/111,681 external-priority patent/US6417168B1/en
Application filed filed Critical
Publication of JP2012017341A publication Critical patent/JP2012017341A/ja
Publication of JP2012017341A5 publication Critical patent/JP2012017341A5/ja
Application granted granted Critical
Publication of JP5719270B2 publication Critical patent/JP5719270B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011224347A 1998-03-04 2011-10-11 腫瘍治療のための組成物および方法 Expired - Lifetime JP5719270B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7678898P 1998-03-04 1998-03-04
US60/076,788 1998-03-04
US09/111,681 1998-07-08
US09/111,681 US6417168B1 (en) 1998-03-04 1998-07-08 Compositions and methods of treating tumors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000534245A Division JP2002505309A (ja) 1998-03-04 1999-03-04 腫瘍治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012017341A JP2012017341A (ja) 2012-01-26
JP2012017341A5 true JP2012017341A5 (https=) 2013-01-10
JP5719270B2 JP5719270B2 (ja) 2015-05-13

Family

ID=26758479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000534245A Pending JP2002505309A (ja) 1998-03-04 1999-03-04 腫瘍治療のための組成物および方法
JP2011224347A Expired - Lifetime JP5719270B2 (ja) 1998-03-04 2011-10-11 腫瘍治療のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000534245A Pending JP2002505309A (ja) 1998-03-04 1999-03-04 腫瘍治療のための組成物および方法

Country Status (13)

Country Link
US (8) US6417168B1 (https=)
EP (2) EP3034093B1 (https=)
JP (2) JP2002505309A (https=)
AT (1) ATE334702T1 (https=)
AU (1) AU757237C (https=)
CA (1) CA2322592A1 (https=)
CY (1) CY1105475T1 (https=)
DE (1) DE69932600T2 (https=)
DK (1) DK1058562T3 (https=)
ES (2) ES2270586T3 (https=)
HK (1) HK1225997A1 (https=)
PT (1) PT1058562E (https=)
WO (1) WO1999044645A1 (https=)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (en) * 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
ES2282120T3 (es) * 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20050239738A1 (en) * 2000-11-17 2005-10-27 Rupert Schmidt-Ullrich Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
WO2003061559A2 (en) * 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
CN100506284C (zh) * 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
AU2002365396A1 (en) * 2001-11-21 2003-06-10 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
US20030202973A1 (en) * 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
WO2004005320A2 (en) * 2002-07-03 2004-01-15 The Curators Of The University Of Missouri ErbB-2 RECEPTOR TARGETING PEPTIDE
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1613205B1 (en) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9427458B2 (en) * 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP6462361B2 (ja) 2011-11-17 2019-01-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 医療診断手順についての情報を収集し、報告し、管理する方法及び技法
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
ES2842201T3 (es) * 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh Inhibidor de HER3 para modulación de radiosensibilidad
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CA2901616A1 (en) 2013-03-14 2014-10-02 Georgetown University Treatment for exposure to nerve agent
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
EP3030268B1 (en) * 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
EP3584312A1 (en) * 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
EP3283111A4 (en) * 2015-04-17 2019-04-17 Celldex Therapeutics, Inc. BIOMARKERS RELATED TO TREATMENT OF CANCER WITH HER3 AND EGFR INHIBITORS
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP7234149B2 (ja) 2017-07-07 2023-03-07 バイエル・ヘルスケア・エルエルシー 注入システム間でデータをピア交換するためのシステム、方法、及び、コンピュータプログラムプロダクト
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
WO2023039613A2 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Lilrb2-specific monoclonal antibodies and methods of their use
WO2024102864A2 (en) * 2022-11-08 2024-05-16 Purdue Research Foundation Multivalent multispecific conjugates and related compositions and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600377A (en) * 1898-03-08 Spring saddle-post
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
EP0160079B1 (en) * 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US5200178A (en) 1988-02-26 1993-04-06 The General Hospital Corporation Method for tumor detection
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
WO1991015230A1 (en) 1990-04-06 1991-10-17 The Trustees Of The University Of Pennsylvania Ligand for the neu gene product
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993014781A1 (en) 1992-01-24 1993-08-05 The Regents Of The University Of California Novel peptides and method for altering the activity of allosteric proteins
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
US6733752B1 (en) * 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
EP0740187B1 (en) 1995-04-28 2004-06-23 Hewlett-Packard Company, A Delaware Corporation Electro-optic display
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
DE69736806T3 (de) * 1996-03-27 2015-10-08 Genentech, Inc. ErbB3 ANTIKÖRPER
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
US6074640A (en) * 1997-10-30 2000-06-13 Uab Research Foundation Enhancement of tumor cell radiosensitivity using single chain intracellular antibodies
US6027892A (en) * 1996-12-30 2000-02-22 Chang Esther H Compositions and methods for reducing radiation and drug resistance in cells
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
DE10124566A1 (de) 2001-05-15 2002-11-21 Zeiss Carl Optisches Abbildungssystem mit Polarisationsmitteln und Quarzkristallplatte hierfür
US6828474B2 (en) 2002-03-06 2004-12-07 National Starch & Chemical Investment Holding Corporation Method of grain production for heterozygous waxy sugary-2 maize
US8561398B2 (en) 2009-05-05 2013-10-22 Florida Renewable Energy Corporation Fluid-based power generation system
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
US9507157B2 (en) 2014-12-17 2016-11-29 Zhen Tang Size-adjustable elliptical laser marker
TWI713998B (zh) 2019-02-22 2020-12-21 南亞塑膠工業股份有限公司 一種含二氧化鈦漿料的製作及應用於回收聚酯纖維

Similar Documents

Publication Publication Date Title
JP2012017341A5 (https=)
Nicoletti et al. Metabotropic glutamate receptors: from the workbench to the bedside
Goffin et al. Epidermal growth factor receptor: pathway, therapies, and pipeline
Yewale et al. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Mitchell et al. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Roskoski Jr ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski Jr The ErbB/HER family of protein-tyrosine kinases and cancer
Schmitz et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions
Camorani et al. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications
JP2011137003A5 (https=)
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
NZ585465A (en) Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
PH12017501908B1 (en) Human anti-cd27 antibodies, methods and uses
AR089083A1 (es) Anticuerpos para receptor de factor de crecimiento epidermico 3 (her3)
EA201300996A1 (ru) Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
NZ590131A (en) Notch-binding agents and antagonists and methods of use thereof
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
SG10201906270VA (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
IL214255B (en) Use of antibodies for preparation of medicaments for treatment of cancer associated with a tumor antigen and methods for diagnosis of cancer associated with a tumor antigen
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
NZ601943A (en) Antibodies against cxcr4
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.